Edgar Braendle
Net worth: - $ as of 2024-03-30
Profile
Edgar Braendle served as the President & Chief Executive Officer at Arup Laboratories, Inc. from 2016 to 2017.
He then worked as the Chief Medical Officer, EVP & Head-Research at Boston Biomedical, Inc. and later as the Chief Medical Officer & Global Head-Development at Sumitomo Dainippon Pharma Oncology, Inc. In 2021, he joined Autolus Therapeutics Plc as the Chief Development Officer & Senior Vice President.
Dr. Braendle holds a doctorate degree from RWTH Aachen University.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
AUTOLUS THERAPEUTICS PLC
-.--% | 2023-02-28 | 0 ( -.--% ) | - $ | 2024-03-30 |
Former positions of Edgar Braendle
| Companies | Position | End |
|---|---|---|
| AUTOLUS THERAPEUTICS PLC | Corporate Officer/Principal | 2024-03-13 |
Arup Laboratories, Inc.
 Arup Laboratories, Inc. Miscellaneous Commercial ServicesCommercial Services Arup Laboratories, Inc. provides clinical and anatomic pathology laboratory services. It offers testing services in the areas of anatomic pathology, pain management, genetics, pediatrics, infectious disease, oncology, and other specialties. The company is headquartered in Salt Lake City, UT. | Chief Executive Officer | 2017-08-10 |
Boston Biomedical, Inc.
 Boston Biomedical, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Sumitomo Chemical Co., Ltd., Boston Biomedical, Inc. is a developer of novel cancer therapeutics with the goal of significantly improving patient outcomes. The private company is based in Norwood, MA. The company's most advanced research programs are focused on investigational agents that inhibit multiple oncogenic pathways, including cancer stemness pathways, and modifying immune responses. The company was founded by Chiang J. Li. Boston Biomedical was acquired by Sumitomo Pharma Co., Ltd. on April 25, 2012 for $2,630 million. | Chief Tech/Sci/R&D Officer | - |
Sumitomo Dainippon Pharma Oncology, Inc.
 Sumitomo Dainippon Pharma Oncology, Inc. BiotechnologyHealth Technology Part of Sumitomo Chemical Co., Ltd., Sumitomo Dainippon Pharma Oncology, Inc. is a developer of novel cancer therapeutics. The private company is based in Cambridge, MA. The company has teams in the US and Japan and is relentlessly committed to advancing purposeful science by transforming new discoveries into meaningful treatments for patients with cancer. Sumitomo Dainippon Pharma Oncology is a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. The company has a diverse and purposeful pipeline of targeted therapies. The CEO of the company is Patricia S. Andrews. | Chief Tech/Sci/R&D Officer | - |
Training of Edgar Braendle
| RWTH Aachen University | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| AUTOLUS THERAPEUTICS PLC | Health Technology |
| Private companies | 3 |
|---|---|
Boston Biomedical, Inc.
Boston Biomedical, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Sumitomo Chemical Co., Ltd., Boston Biomedical, Inc. is a developer of novel cancer therapeutics with the goal of significantly improving patient outcomes. The private company is based in Norwood, MA. The company's most advanced research programs are focused on investigational agents that inhibit multiple oncogenic pathways, including cancer stemness pathways, and modifying immune responses. The company was founded by Chiang J. Li. Boston Biomedical was acquired by Sumitomo Pharma Co., Ltd. on April 25, 2012 for $2,630 million. | Commercial Services |
Arup Laboratories, Inc.
Arup Laboratories, Inc. Miscellaneous Commercial ServicesCommercial Services Arup Laboratories, Inc. provides clinical and anatomic pathology laboratory services. It offers testing services in the areas of anatomic pathology, pain management, genetics, pediatrics, infectious disease, oncology, and other specialties. The company is headquartered in Salt Lake City, UT. | Commercial Services |
Sumitomo Dainippon Pharma Oncology, Inc.
Sumitomo Dainippon Pharma Oncology, Inc. BiotechnologyHealth Technology Part of Sumitomo Chemical Co., Ltd., Sumitomo Dainippon Pharma Oncology, Inc. is a developer of novel cancer therapeutics. The private company is based in Cambridge, MA. The company has teams in the US and Japan and is relentlessly committed to advancing purposeful science by transforming new discoveries into meaningful treatments for patients with cancer. Sumitomo Dainippon Pharma Oncology is a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. The company has a diverse and purposeful pipeline of targeted therapies. The CEO of the company is Patricia S. Andrews. | Health Technology |
- Stock Market
- Insiders
- Edgar Braendle
